|

Cariprazine Depot MTD Clinical Trials

1 actively recruiting trial

No change since May 2026

Pipeline

Phase 1/2: 1

Top Sponsors

  • Mapi Pharma Ltd.1

Indications

  • Bipolar 1 Disorder1
  • Major Depressive Disorder (MDD)1
  • Major Depressive Disorder1
  • Bipolar I Disorder1
  • Schizophrenia1

Other1 trial

Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.